RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. (RLMD) on January 3, 2024. The report discloses a material event regarding the departure of a senior officer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements.
Material Changes
On January 3, 2024, Dr. Cedric O'Gorman concluded his service as Chief Medical Officer of the Company. The departure was mutually agreed upon between Dr. O'Gorman and the Company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the executive departure.
Key Investor Verification Points
- Confirm the effective date of Dr. O'Gorman's departure (January 3, 2024).
- Verify if a successor Chief Medical Officer has been appointed or if the role is currently vacant.
- Review subsequent filings for any impact of this departure on ongoing clinical trials or regulatory submissions.